U.S. License Holder:
Bioverativ Therapeutics Inc.
Date of License:
February-04-2022
Last Update:
Sep-30-2024
FDA-Approved Indications
ENJAYMO (sutimlimab-jome) is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).